Navidea Biopharmaceuticals (NAVB) Stock Chart & Stock Price History $0.0005 0.00 (0.00%) As of 07/24/2025 Add Compare Share Share Chart Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock Navidea Biopharmaceuticals Stock Price Performance The Navidea Biopharmaceuticals (NAVB) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 50.00%, with a year-to-date return of 400.00%. In the past month, the stock has increased 150.00%, reflecting recent market activity. As of the latest close, Navidea Biopharmaceuticals traded at $0.00 with a market cap of $50 thousand and volume of 5,377 shares. Five years ago, the stock traded at $4.79, representing a 99.99% decrease over that period. At the time, it had a market cap of $111.16 million and a volume of 150,807 shares. Receive NAVB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+400.00%1 Month Performance+150.00%3 Month Performance+150.00%Year-To-Date Performance+400.00%1 Year Performance-50.00%5 Year Performance-99.99% NAVB Stock Chart for Friday, July, 25, 2025 NAVB Chart by TradingView Navidea Biopharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/24/2025$0.00$0.00$0.00$0.005,377 shs$50,000.0007/23/2025$0.00$0.00+400.00%$0.00$0.005,377 shs$50,000.0007/22/2025$0.00$0.00$0.00$0.002,266 shs$10,000.0007/21/2025N/A$0.00$0.00$0.0014,025 shs$10,000.0007/18/2025$0.00$0.00$0.00$0.00664 shs$10,000.0007/17/2025$0.00$0.00-50.00%$0.00$0.00664 shs$10,000.0007/16/2025$0.00$0.00$0.00$0.001,164 shs$20,000.0007/15/2025$0.00$0.00$0.00$0.00125 shs$20,000.0007/14/2025$0.00$0.00$0.00$0.00125 shs$20,000.0007/11/2025$0.00$0.00$0.00$0.0014,470 shs$20,000.00 Get the Latest News and Ratings for NAVB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/10/2025$0.00$0.00-33.33%$0.00$0.0014,470 shs$20,000.0007/09/2025$0.00$0.00$0.00$0.008,000 shs$30,000.0007/08/2025$0.00$0.00+50.00%$0.00$0.008,000 shs$30,000.0007/07/2025$0.00$0.00$0.00$0.00105 shs$20,000.0007/04/2025$0.00$0.00$0.00$0.0040 shs$20,000.0007/03/2025$0.00$0.00$0.00$0.0032,388 shs$20,000.0007/02/2025$0.00$0.00-80.00%$0.00$0.0032,388 shs$20,000.0007/01/2025$0.00$0.00$0.00$0.005,492 shs$100,000.0006/30/2025$0.00$0.00+900.00%$0.00$0.005,492 shs$100,000.0006/27/2025$0.00$0.00-50.00%$0.00$0.0015,514 shs$10,000.0006/26/2025$0.00$0.00$0.00$0.00820 shs$20,000.0006/25/2025$0.00$0.00$0.00$0.00159 shs$20,000.0006/24/2025$0.00$0.00$0.00$0.0012,522 shs$20,000.00 Related Companies Scopus BioPharma Stock Chart Vaxxinity Stock Chart Evelo Biosciences Stock Chart Comera Life Sciences Stock Chart Genocea Biosciences Stock Chart Genocea Biosciences Stock Chart Aridis Pharmaceuticals Stock Chart Statera Biopharma Stock Chart Ampio Pharmaceuticals Stock Chart eFFECTOR Therapeutics Stock Chart Receive NAVB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NYSE:NAVB) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
